Format

Send to

Choose Destination
See comment in PubMed Commons below
J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii33-44. doi: 10.1093/jac/dkr097.

FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.

Collaborators (117)

Corral J, Giugno E, Gonzalez Arzac Mdel R, Maurizi D, Altclas J, Ambasch G, Jasovich A, Minguez AR, Oliva ME, Teglia O, Bergallo C, Mastruzzo MA, Isabel Morera G, Scapellato PG, Lamberghini R, Mykietiuk A, Remolif C, Barros Monge MJ, Enriqueta Campos Barker MI, Chernilo Steinmann SM, Gaete Gutierrez PA, Muñoz Vejar SS, Calvo Arellano MA, Chahin Anania CE, Jauregui Cruz A, Amaya Tapia G, Acuna Kaldman M, Noriega E, Matos Prado ED, Ramos C, Andreeva I, Abyshev R, Antonovsky YA, Balyuzek M, Esina AL, Gorelov A, Khrustalev OA, Kozlov RS, Novozhenok V, Popova VB, Sobchenko S, Trofimov V, Yakovlev S, Zhidkov K, Ambert LG, Fierbinteau CG, Ionescu V, Muresan MM, Tanaseanu CM, Georgiev O, Hodzhev V, Marinov R, Metev H, Peneva M, Popov D, Simeonova M, Krastins I, Lovcinovsk V, Silins V, Svarcberga V, Bargon J, Bauer T, Bergmann R, Meyer FJ, Mueller T, Welte T, Glaeser S, Hammerl P, Kern H, Krueger S, Kujath P, Lies A, Schaberg T, Schmalz O, Schütte W, Chazan R, Górecka D, Rogala B, Antczak A, Grodzicki T, Jahnz-Rö K, Milanowski J, Nalepa P, Wróbel-Rajzer M, Szelerska-Twardosz H, Grzelewska-Rzymowska I, Kachel T, Marciniak A, Panaszek B, Szczeklik A, Kozielski J, Harat R, Jastrzebsk D, Juszczak J, Labij V, Vetter N, Bolitschek J, Eckmayr J, Molnár S, Pápai-Székely Z, Szegedi J, Vinkler I, Borscchivskyy M, Dziublyk O, Dzyak GV, Kraydaschenko O, Mostovoy YM, Rudyk IS, Sushko V, Vizir V, Bhattacharya AK, Chakrapan M, D'Souza G, Malpani GS, Mehta P, Rao KN, Talwar D.

Author information

1
Mount Sinai Hospital/University Health Network, Toronto, Ontario, Canada. dlow@mtsinai.on.ca

Abstract

OBJECTIVES:

Ceftaroline (active form of the prodrug ceftaroline fosamil) is a novel cephalosporin with activity against pathogens commonly associated with community-acquired pneumonia (CAP), including Streptococcus pneumoniae and Gram-negative pathogens. This randomized, double-blind, Phase III study evaluated the efficacy and safety of ceftaroline fosamil in treating patients with CAP. The primary objective was to determine non-inferiority [lower limit of 95% confidence interval (CI) ≥ -10%] of clinical cure rates achieved with ceftaroline fosamil compared with those achieved with ceftriaxone in the clinically evaluable (CE) and modified intent-to-treat efficacy (MITTE) populations.

METHODS:

Patients hospitalized in a non-intensive care unit setting with CAP of Pneumonia Outcomes Research Team (PORT) risk class III or IV requiring intravenous (iv) therapy were randomized (1:1) to receive 600 mg of ceftaroline fosamil iv every 12 h or 1 g of ceftriaxone iv every 24 h. Clinical cure, microbiological response, adverse events (AEs) and laboratory tests were assessed. FOCUS 2 registration number NCT00509106 (http://clinicaltrials.gov/ct2/show/NCT00509106).

RESULTS:

The study enrolled 627 patients, 315 of whom received ceftaroline fosamil and 307 of whom received ceftriaxone. Patients in both treatment groups had comparable baseline characteristics. Clinical cure rates were as follows: CE population, 82.1% (193/235) for ceftaroline fosamil and 77.2% (166/215) for ceftriaxone [difference (95% CI), 4.9% (-2.5, 12.5)]; and MITTE population, 81.3% (235/289) for ceftaroline fosamil and 75.5% (206/273) for ceftriaxone [difference (95% CI), 5.9% (-1.0, 12.7)]. Clinical cure rates for CAP caused by S. pneumoniae in the microbiological MITTE (mMITTE) population were 83.3% (35/42) and 70.0% (28/40) for ceftaroline fosamil and ceftriaxone, respectively. Ceftaroline fosamil and ceftriaxone were well tolerated, with similar rates of AEs, serious AEs, deaths and discontinuations due to an AE. The most common AEs for ceftaroline fosamil-treated patients were diarrhoea, headache, hypokalaemia, insomnia and phlebitis, and the most common AEs for ceftriaxone-treated patients were diarrhoea, insomnia, phlebitis and hypertension.

CONCLUSIONS:

Ceftaroline fosamil achieved high clinical cure and microbiological response rates in patients hospitalized with CAP of PORT risk class III or IV. Ceftaroline fosamil was well tolerated, with a safety profile that is similar to that of ceftriaxone and other cephalosporins. Ceftaroline fosamil is a promising agent for the treatment of CAP.

PMID:
21482568
DOI:
10.1093/jac/dkr097
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Support Center